Researchers Upgrade Proton Therapy Beam Model Using Advanced GPU-Based Monte Carlo Simulation
Scientists at MD Anderson Cancer Center have developed an improved beam model for the Hitachi PROBEAT proton therapy system, using double-Gaussian distributions to more accurately simulate particle behavior in a GPU-accelerated Monte Carlo dose engine. The work addresses the need for an independent dose calculation tool that can serve both clinical quality assurance and advanced research purposes. More accurate phase space modeling could improve treatment precision and expand research capabilities at the institution's proton therapy center.
Researchers from MD Anderson Cancer Center have submitted a preprint describing upgrades to an in-house Fast Monte Carlo dose engine used with the Hitachi PROBEAT proton therapy system. The key advancement is the adoption of double-Gaussian distributions—rather than simpler single-Gaussian models—for both the spatial and opening angle distributions of proton beam particles, yielding more accurate phase space files. Such an independent dose engine operates separately from the clinic's commercial treatment planning system (TPS), making it a valuable tool for patient quality assurance (QA) verification and for implementing experimental features not available in commercial software. The GPU-based architecture of the engine enables computationally intensive Monte Carlo simulations to run at clinically practical speeds. The authors indicate the upgraded model is expected to improve performance across both clinical and research applications at MD Anderson's expanded proton therapy center. The study includes seven figures and tables supporting the beam modeling methodology and validation. As a preprint posted to arXiv, the work has not yet undergone formal peer review.
What's missing
Key study limitations and open questions include: the preprint has not yet been peer-reviewed; quantitative validation results comparing the upgraded double-Gaussian model against measured beam data or the existing single-Gaussian model are not described in the abstract; it is unclear whether the model has been tested across the full range of clinical beam energies and field configurations used at MD Anderson; and the generalizability of the beam model to other proton therapy systems or institutions is not addressed.
What different sources said
- arXiv physicsCenter
Beam modelling of Hitachi PROBEAT proton therapy system for a GPU-based Fast Monte Carlo dose engine
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.